VK2735
VANQUISH 1
Viking Therapeutics · Phase 3 · Active, not recruiting · Enrollment 4500
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Placebo Assignment | Population n/r | n/r | n/r | n/r | n/r |
| Active Assignment (Dose 1) | Population n/r | n/r | n/r | n/r | n/r |
| Active Assignment (Dose 2) | Population n/r | n/r | n/r | n/r | n/r |
| Active Assignment (Dose 3) | Population n/r | n/r | n/r | n/r | n/r |